Trials / Completed
CompletedNCT05380635
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
Phase 2a Study of Systemic PK and Serial ECG Determinations Following 8 Weeks of HyBryte Treatment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Soligenix · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the blood levels of hypericin and any electrocardiogram (ECG) changes during 8 weeks of HyBryte (topical hypericin ointment) photodynamic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hypericin | HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment. |
Timeline
- Start date
- 2022-05-09
- Primary completion
- 2022-08-16
- Completion
- 2022-08-16
- First posted
- 2022-05-19
- Last updated
- 2023-06-07
- Results posted
- 2023-06-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05380635. Inclusion in this directory is not an endorsement.